Last reviewed: June 27, 2026
Last updated: June 27, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy (semaglutide) and Zepbound (tirzepatide) represent two distinct approaches to GLP-1 therapy, each backed by large clinical trials showing significant weight loss. Both reduce hunger and improve blood sugar control, but tirzepatide activates an additional hormone pathway that may produce greater fat loss for certain patients. Choosing between them depends on your individual response, genetics, and health profile.
How Wegovy and Zepbound Work Differently
Wegovy contains semaglutide, a medication that activates one hormone receptor called GLP-1. This receptor sits on nerve cells in your brain that control appetite and on cells in your digestive tract that slow stomach emptying. By stimulating the GLP-1 pathway alone, semaglutide reliably reduces hunger and food intake, making patients feel fuller longer after smaller meals.
Zepbound contains tirzepatide, which activates two hormone receptors: GLP-1 and GIP (glucose-dependent insulinotropic peptide). This dual-receptor activation creates a synergistic effect—your body receives signals from both pathways simultaneously. Clinical evidence suggests this combination produces greater weight loss than single-pathway activation, with some patients losing 20% or more of their body weight in one year.
Clinical Trial Results: Weight Loss Outcomes Compared
The STEP trials evaluated semaglutide across multiple studies, showing average weight loss of 10% to 18% of body weight depending on dose and patient population. Patients receiving the highest dose experienced the most consistent results, though side effects also increased with higher doses. These outcomes represent genuine, sustained weight reduction compared to placebo, which showed minimal changes.
The SUMO trials tested tirzepatide using the same study design as Wegovy's trials. Patients on tirzepatide showed average weight loss ranging from 15% to 22% of their starting body weight. The SUMO-4 trial directly compared tirzepatide to semaglutide in the same patient population, and tirzepatide consistently produced greater weight loss across all measured timepoints. This difference became more pronounced after 12 months of treatment, suggesting tirzepatide's dual-pathway approach delivers additional benefits over time.
Individual Response and Genetic Factors
Not every patient responds equally to the same medication. Some people lose weight faster on semaglutide, while others see better results with tirzepatide. This variation reflects differences in how your body's hormone pathways function at the genetic level. Genetic variants in the GLP1R gene, GIPR gene, and other appetite-control genes influence whether you respond more strongly to single-pathway or dual-pathway activation.
PlexusDx offers the Precision Peptide Genetic Test, which analyzes 14 metabolic pathways and 49 peptides to reveal your individual genetic predispositions. Testing identifies whether you carry variants associated with stronger GLP-1 pathway sensitivity or whether you might benefit more from tirzepatide's GIP activation. This personalized insight removes guesswork from treatment selection and increases your likelihood of success with your chosen medication.
Side Effects and Tolerability Differences
Both medications cause similar side effects, primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation occur most frequently during the first weeks of treatment as your digestive system adjusts. These effects are usually temporary and decrease as your body becomes accustomed to the medication. Semaglutide tends to produce a slightly milder initial side effect profile for some patients, though individual tolerance varies widely.
Tirzepatide's dual-pathway activation occasionally produces more pronounced nausea in early treatment phases, though many patients tolerate it well after dose adjustments. The advantage is that tirzepatide often reaches effective weight loss at lower doses than semaglutide requires, potentially reducing the cumulative side effect burden over time. Your personal medical history, other medications, and gastrointestinal sensitivity should inform your choice alongside clinical efficacy data.
Cost and Access: Making Either Medication Affordable
Brand-name Wegovy and Zepbound carry substantial out-of-pocket costs, often exceeding $900 monthly without insurance coverage. PlexusDx offers compounded versions of both medications at significantly lower prices: compounded semaglutide injection starts at $149 per month, while compounded tirzepatide injection starts at $249 per month. Your price remains flat regardless of dose increases—dose adjustments do not trigger higher monthly costs.
PlexusDx compounds all medications through licensed 503A pharmacies, operates in all 50 states, requires no insurance, and charges no membership fees. Both semaglutide and tirzepatide qualify for HSA and FSA savings accounts, making them eligible for pre-tax spending. If you wish to explore your genetic suitability for either medication before committing to long-term treatment, the Precision Peptide Genetic Test costs $99 as an add-on after your first month of any PlexusDx therapy.
Which Medication Should You Choose?
Selecting between Wegovy and Zepbound involves weighing clinical evidence, personal health factors, and individual response patterns. If you prefer a single-pathway approach with a slightly gentler initial side effect profile, semaglutide may suit you well. If clinical trial data showing greater average weight loss appeals to you, or if you have genetic predispositions favoring dual-pathway activation, tirzepatide offers compelling advantages.
Starting with genetic testing through PlexusDx's Precision Peptide Genetic Test provides objective data about your peptide-pathway sensitivity before you commit to either medication long-term. Many patients work with their healthcare provider to trial one medication for 8-12 weeks, assess their personal response, and adjust or switch if needed. PlexusDx supports this approach by offering both medications at flat monthly rates that accommodate dose changes without price increases, making it financially feasible to find your optimal treatment.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is tirzepatide actually better than semaglutide for weight loss?
Clinical trials show tirzepatide produces greater average weight loss than semaglutide (15–22% versus 10–18% of body weight). However, 'better' depends on your individual genetics and health profile. Some patients respond equally well to semaglutide and prefer its side effect profile. PlexusDx's Precision Peptide Genetic Test identifies whether your genetic variants favor one pathway over the other.
Can I switch from Wegovy to Zepbound if one doesn't work?
Yes. Many patients trial one medication for 8–12 weeks to assess their personal response, then switch if needed. PlexusDx offers both semaglutide and tirzepatide at flat monthly prices, making it financially practical to find the medication that works best for your body without unexpected cost increases during transitions.
How much does compounded tirzepatide cost at PlexusDx?
PlexusDx compounded tirzepatide injection starts at $249 per month. Your price remains flat as your dose increases—you pay $249 regardless of whether you're on a microdose or a full therapeutic dose. No insurance is required, and the medication qualifies for HSA and FSA accounts.
Are compounded versions of Wegovy and Zepbound as effective as brand-name?
PlexusDx compounds all medications through licensed 503A pharmacies using the identical pharmaceutical compounds as brand-name versions. The active ingredient is the same; the difference is price and accessibility. Many patients achieve the same weight loss results with compounded medications at a fraction of the brand-name cost.
What is the Precision Peptide Genetic Test, and should I get it?
PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and identifies genetic variants in GLP1R, GIPR, FTO, MC4R, and other genes that influence your appetite and weight-loss response. For $99 after your first month of treatment, it reveals whether you're genetically predisposed to respond better to semaglutide, tirzepatide, or alternative peptide approaches—removing guesswork from your treatment plan.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Meal Prep on Ozempic: How to Plan When Your Appetite Has Changed
Understanding the Average Weight Loss Per Week on Zepbound